Related Experiment Video

Updated: Mar 1, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.8K

MicroRNA-338-3p inhibits thyroid cancer progression through targeting AKT3

Guo-Qing Sui1, Dan Fei1, Feng Guo1

  • 1Department of Ultrasound, The China-Japan Union Hospital of Jilin UniversityChangchun 130033, China.

American Journal of Cancer Research
|June 1, 2017
PubMed

Insights

microRNA-338-3p (miR-338-3p) acts as a tumor suppressor in thyroid cancer. Its downregulation promotes cancer progression, while restoring miR-338-3p inhibits growth by targeting the oncogene AKT3.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • microRNA-338-3p (miR-338-3p) is linked to various cancers.
  • Its specific role in thyroid cancer pathogenesis is not well understood.

Purpose of the Study:

  • To investigate the function and mechanism of miR-338-3p in thyroid cancer.
  • To determine if miR-338-3p acts as a tumor suppressor.

Main Methods:

  • In vitro and in vivo experiments were conducted.
  • Thyroid cancer tissues and cell lines were analyzed for miR-338-3p expression.
  • Target validation was performed using techniques like Western blotting and siRNA.
  • Nude mouse xenograft models were used for tumorigenesis studies.

Main Results:

  • miR-338-3p was found to be downregulated in thyroid cancer tissues and cell lines.
  • Lower miR-338-3p expression correlated with advanced clinical stage and lymph node metastasis.
  • Overexpression of miR-338-3p inhibited thyroid cancer cell proliferation, migration, invasion, and in vivo tumor growth.
  • AKT3 was identified as a direct target of miR-338-3p, and its suppression mediated the anti-cancer effects.

Conclusions:

  • miR-338-3p functions as a tumor suppressor in thyroid cancer.
  • It inhibits cancer cell growth and invasion by targeting the oncogene AKT3.
  • Restoring miR-338-3p levels may offer a therapeutic strategy for thyroid cancer.
Keywords:
AKT3Thyroid cancerinvasionmiR-338-3pproliferation

More Related Videos

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

18.1K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.4K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K